Renal cell carcinoma : translational biology, personalized medicine, and novel therapeutic targets

Annotation This book provides a comprehensive look at renal cell carcinoma, exploring its biology as well as current and future molecular targets for renal cancer carcinoma Front Matter....Pages i-xi Front Matter....Pages 1-1 The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies....Pages 3-25 Molecular Biology of Clear Cell Renal Carcinoma....Pages 27-47 HIF Biology in RCC: Implications for Signaling, Disease Progression, and Treatment....Pages 49-68 Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC....Pages 69-89 Molecular Characterization of Renal Cell Carcinoma....Pages 91-111 Front Matter....Pages 113-113 Targeting the VEGF Pathway in Renal Cell Carcinoma....Pages 115-133 Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma....Pages 135-160 Research Translation and Personalized Medicine....Pages 161-191 Epigenetic Targeting and Histone Deacetylase Inhibition in RCC....Pages 193-211 C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma....Pages 213-238 Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies....Pages 239-252 Carbonic Anhydrase IX: Its Role as a Biomarker, Diagnostic, and Therapeutic Target in Renal Cell Carcinoma....Pages 253-270 Presurgical Therapy for Renal Cell Carcinoma and Implications for Window-of-Opportunity Trials....Pages 271-282 Mechanisms of Resistance to VEGF-Directed Therapy and Implications for Future Trial Design....Pages 283-303 Vaccine-Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma....Pages 305-322 Back Matter....Pages 323-327 This volume examines every major topic area in the modern era of renal carcinoma biology and treatment. The unique and intricate genetics of this cancer are highly distinct from most other tumors, and the advances made in this cancer beyond VHL biology have been intrinsically driven by discoveries from familial renal cell carcinomas linked with newer large scale genomic efforts in sporadic disease. These genetic findings fuel strategies to analyze and define sporadic tumors for greater accuracy in prognosis and prediction of response to therapy. Additional topics include major new therapeutic strategies that harness these biological discoveries, in particular angiogenic, energy metabolism, chromatin remodeling, tumor microenvironment, and classical signaling pathways. This text will bring all of these avenues of investigation together for readers interested in understanding the dynamics of this field in the last decade and anticipating a continued steep trajectory in advancements toward the cure of this disease in its many manifestations